secwatch.observer — SEC 8-K summary
======================================

Issuer:     Entera Bio Ltd. (ENTXW)
CIK:        0001638097
Form:       8-K
Filed at:   2023-05-05T23:59:59+00:00
Accession:  0001178913-23-001714
Event type: earnings
Sentiment:  neutral
Materiality: 0.55
Item codes: 2.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Entera Bio Q1 net loss $2.2M vs $3.8M YoY; cash $10.7M into Q3 2024
-------------------------------------------------------------------

- Net loss of $2.2M, $0.08 per share, compared to $3.8M, $0.13 per share in Q1 2022.
- Cash and equivalents $10.7M as of Mar 31, 2023; expects cash to fund ops into Q3 2024.
- R&D expenses $0.9M (down 47% YoY); G&A expenses $1.3M (down 41% YoY).
- Plans to initiate PK study of oral PTH(1-34) for hypoparathyroidism H1 2023, topline H2 2023.
- Amgen research collaboration discontinued by mutual agreement after 4+ years.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1638097/000117891323001714/0001178913-23-001714-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1638097/000117891323001714/form8k.htm
  HTML page:      https://secwatch.observer/filing/0001178913-23-001714

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer